Summary of findings table ‐ Daratumumab plus standard therapy vs usual care
Overall survival (at 36 months) · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower overall survival (at 36 months) compared with standard therapy (moderate certainty).
1 finding from 1 review
- Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple… 2024 · Cochrane Headline outcomes onlyHR 0.64 [0.53, 0.76]2 studies · 1443 participantsModerate